This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Cost-effectiveness Model of Strategy Assessment

Stephen L. Cochi, MD; Claire V. Broome, MD; Allen W. Hightower, MS

JAMA. 1985;253(4):521-529.

Abstract
Hemophilus influenzae type b (HIB) is the leading cause of bacterial meningitis in the United States. Efforts are under way to develop vaccines immunogenic in children younger than 18 months, but clinical efficacy of a previously developed HIB polysaccharide vaccine has already been established in children aged 18 months or older. We developed a cost-effectiveness model to evaluate immunizing US children with this HIB polysaccharide vaccine pending development of a more immunogenic product. The model permitted comparison of the impact of alternative strategies for use of the vaccine, including universal use at 18 or 24 months of age, use of a second dose after primary immunization, and use in high-risk groups such as day-care-center attendees. Universal vaccination at 18 or 24 months of age resulted in similar estimates of disease prevented, as a consequence of the higher expected efficacy and duration of immunity for the vaccine when given at 24 months. Overall, the implementation of routine childhood immunization against HIB at 18 months of age was the most cost-effective strategy. Universal vaccination at 18 months of age combined with a second dose for day-care—center attendees would substantially increase the number of cases prevented, with a minimal increase in costs. Universal vaccination with a two-dose schedule beginning at 18 months of age could prevent the most disease.

(JAMA 1985;253:521-529)

Author Affiliations
From the Division of Bacterial Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta.

Footnotes
Reprint requests to Division of Bacterial Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333 (Dr Cochi).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Roush et al.
JAMA 2007;298:2155-2163.
ABSTRACT | FULL TEXT  

Long Survival Following Bacterial Meningitis-Associated Brain Destruction
Repertinger et al.
J Child Neurol 2006;21:591-595.
ABSTRACT  

Immunologic Response to Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Risk Factors for Carriage among Hib Carriers and Noncarriers in Southwestern Alaska
Baggett et al.
CVI 2006;13:620-626.
ABSTRACT | FULL TEXT  

Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001
Zhou et al.
Arch Pediatr Adolesc Med 2005;159:1136-1144.
ABSTRACT | FULL TEXT  

Impact of Universal Haemophilus influenzae Type b Vaccination Starting at 2 Months of Age in the United States: An Economic Analysis
Zhou et al.
Pediatrics 2002;110:653-661.
ABSTRACT | FULL TEXT  

Active Immunization in the United States: Developments over the Past Decade
Dennehy
Clin. Microbiol. Rev. 2001;14:872-908.
ABSTRACT | FULL TEXT  

Ethics and Immunization Policy: Promoting Dialogue to Sustain Consensus
Feudtner and Marcuse
Pediatrics 2001;107:1158-1164.
ABSTRACT | FULL TEXT  

Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates
Peltola
Clin. Microbiol. Rev. 2000;13:302-317.
ABSTRACT | FULL TEXT  

Cost of Chickenpox in Canada: Part II. Cost of Complicated Cases and Total Economic Impact
Law et al.
Pediatrics 1999;104:7-14.
ABSTRACT | FULL TEXT  

Clinical and Economic Impact of a Combination Haemophilus influenzae and Hepatitis B Vaccine: Estimating Cost-effectiveness Using Decision Analysis
Fendrick et al.
Arch Pediatr Adolesc Med 1999;153:126-136.
ABSTRACT | FULL TEXT  

Responses of Children Immunized with Capsular Polysaccharide of Hemophilus influenzae Type b, by David H. Smith, MD, et al, Pediatrics, 1973;52:637-644; and Haemophilus influenzae Type b Capsular Polysaccharide Vaccine in Children: A Double-blind Field Study of 100 000 Vaccinees 3 Months to 5 Years of Age in Finland, by Heikki Peltola, MD et al, Pediatrics, 1977;60:730-737
Peter
Pediatrics 1998;102:252-254.
ABSTRACT | FULL TEXT  

Bacterial Meningitis in the United States in 1995
Schuchat et al.
NEJM 1997;337:970-976.
ABSTRACT | FULL TEXT  

Prevention of Hepatitis B Virus Transmission by Immunization: An Economic Analysis of Current Recommendations
Margolis et al.
JAMA 1995;274:1201-1208.
ABSTRACT  

Cost-effectiveness of a Routine Varicella Vaccination Program for US Children
Lieu et al.
JAMA 1994;271:375-381.
ABSTRACT  

Adoption of a New Haemophilus influenzae Type b Vaccine Recommendation
FREED et al.
Arch Pediatr Adolesc Med 1993;147:124-128.
ABSTRACT  

Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era
Adams et al.
JAMA 1993;269:221-226.
ABSTRACT  

Severity and Frequency of Sequelae of Bacterial Meningitis in Alaska Native Infants: Correlation With a Scoring System for Severity of Sequelae
Letson et al.
Arch Pediatr Adolesc Med 1992;146:560-566.
ABSTRACT  

Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature: Are the Methods Being Used Correctly?
Udvarhelyi et al.
ANN INTERN MED 1992;116:238-244.
ABSTRACT  

Spectrum of Invasive Haemophilus influenzae Type b Disease in Adults
Takala et al.
Arch Intern Med 1990;150:2573-2576.
ABSTRACT  

Haemophilus B Polysaccharide Vaccine: Antibody Kinetics in 17- to 71-Month-Old Children
Ramsey et al.
Arch Pediatr Adolesc Med 1989;143:28-30.
ABSTRACT  

Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease
Leung and Jadavji
The Journal of the Royal Society for the Promotion of Health 1988;108:180-181.
 

A Day Care--Based Study of the Efficacy of Haemophilus b Polysaccharide Vaccine
Harrison et al.
JAMA 1988;260:1413-1418.
ABSTRACT  

Cluster of Haemophilus influenzae Type b Infections in Adults
Smith et al.
JAMA 1988;260:1446-1449.
ABSTRACT  

Listeriosis in the United States: 1980-1982
Ciesielski et al.
Arch Intern Med 1988;148:1416-1419.
ABSTRACT  

Recommendations of the Immunization Practices Advisory Committee (ACIP) Update: Prevention of Haemophilus influenzae Type b Disease
Arch Pediatr Adolesc Med 1988;142:419-420.
ABSTRACT  

Update: Prevention of Haemophilus influenzae Type b Disease
JAMA 1988;259:798-804.
 

Haemophilus influenzae b Polysaccharide Vaccine: Physician Acceptance and Use of a New Vaccine
Cochi et al.
Arch Pediatr Adolesc Med 1986;140:1226-1230.
ABSTRACT  

Bacterial Meningitis in Arizona American Indian Children
Yost et al.
Arch Pediatr Adolesc Med 1986;140:943-946.
ABSTRACT  

Secondary Haemophilus influenzae Type b in Day-care Facilities: Risk Factors and Prevention
Fleming et al.
JAMA 1985;254:509-514.
ABSTRACT  

Leads from the MMWR
JAMA 1985;253:2630-2638.
 

Haemophilus influenzae Type b in Day Care Centers-Reply
Pichichero and Redmond
JAMA 1985;253:2647-2648.
ABSTRACT  

Is Hemophilus influenzae Type b Disease Preventable?
Ward
JAMA 1985;253:554-556.
ABSTRACT